Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company dedicated to addressing neuroinflammation. Its mission is to make a significant impact on patients and society by developing safe, oral medications for Alzheimer's disease and various rare diseases. The company's headquarters are located in Jupiter, Florida, specifically at 1001 North US Highway 1, Suite 504, Jupiter, FL 33477.

The company's core product is JOTROL™, an enhanced orally administered resveratrol formulation. JOTROL™ is designed to deliver therapeutically relevant and safe levels of resveratrol with superior oral bioavailability, overcoming limitations of conventional resveratrol. Jupiter Neurosciences focuses on developing treatments for central nervous system (CNS) disorders such as Parkinson's disease, Alzheimer's disease, Mild Cognitive Impairment, and traumatic brain injury, as well as rare diseases including Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and MELAS. In addition to its pharmaceutical pipeline, the company also operates a consumer longevity product line called Nugevia™, which utilizes the same proprietary JOTROL™ technology.

Jupiter Neurosciences is led by Christer Rosén, who serves as Chairman and CEO. Other key executives include Alison D. Silva (President, Chief Business Officer and Director), Saleem Elmasri (Chief Financial Officer), Alexander Rosen (Chief Administrative Officer), and Dr. Marshall Hayward (Chief Scientific Officer and Director). The company operates with a dual-path strategy, advancing both its pharmaceutical pipeline and its consumer longevity products. In November 2025, the FDA cleared its Investigational New Drug (IND) application, authorizing a Phase IIa clinical trial for JOTROL™ in Parkinson's disease. The Nugevia™ consumer longevity line was launched in 2025, and the company has been actively presenting its clinical and commercial progress at various investor conferences in early 2026.